Paradigm Global Events is again proud to present our Orphan Drugs and Rare Diseases 2019 Americas – West Coast. It’s the 10th in the series of our Flagship tri-annual Orphan Drugs and Rare Diseases event, this congress will provide you with a comprehensive insight in establishing well-informed strategic decisions.

The global rare disease diagnostics market was valued $45.18 billion in 2017 and is anticipated to reach $86.15 billion by 2025. Factors such as high incidence of rare diseases, presence of large numbers of research and development facilities for rare diseases, significant number of rare disease registries, high diagnosis rare of rare diseases in countries of North America, and extensive investments in different therapeutic areas are driving the growth of the North America rare disease diagnostics market. However, the Asia Pacific region is expected to register the highest CAGR of 9.22% during the forecast period 2018-2025.

The growth of the global orphan drugs market is increasing at a rapid pace due to the growing rare diseases. With further growth anticipated to meet the high unmet demand for more efficacious drugs with very little side effects. Although, the number of people affected by rare diseases are considerably low, the return of investment is high due to the high cost of orphan drugs. Global collaboration is also likely to fuel growth. FDA recognizes the significance of orphan drugs in the treatment of rare debilitating, life-threatening diseases therefore supporting stakeholders to promote research and development in this area.

However, the industry is never without its challenges. Factors such as the lack of diagnosis, government policies, awareness and funding for R&D, along with long diagnostic delays, high initial investment that leads to higher per patient treatment cost, reimbursement uncertainties and high cost of drug development are hindering the market.

Orphan Drugs & Rare Diseases 2019 Americas – West Coast will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organizations, orphan drugs developers as well as regional and local manufacturers.  We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialization, policies, reimbursement, pricing and more.